Drugs / MEM 3454
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00725855 | Aug 2008 → Mar 2009 | schizophrenia | Memory Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT00604760 | Dec 2007 → Feb 2009 | schizophrenia | Memory Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT00454870 | Feb → Oct 2007 | Alzheimer disease | Memory Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEM 3454 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00725855 ↗ |
| Action | Activate | “MEM 3454 is a novel nicotinic alpha-7 receptor selective partial agonist” NCT00454870 ↗ |